6 days Ago By Defense World Staff
Alliancebernstein L.P. cut its holdings in Dyne Therapeutics, Inc.
(NASDAQ:DYN – Free Report) by 16.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 153,218 shares of the company’s stock after selling 30,993 shares during the period.
Alliancebernstein L.P. owned about 0.
15% of Dyne Therapeutics worth $3,610,000 at the end of the most recent quarter. A number of other institutional investors have also made changes to their positions in DYN. Bank of New York Mellon Corp increased its position in shares of Dyne Therapeutics by 0.
3% during the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock worth $5,532,000 after purchasing an additional 698 shares during the last quarter. KBC Group NV grew its stake in shares of Dyne Therapeutics by 45.
3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after buying an additional 978 shares in the last quarter. E Fund Management Co.
Ltd. increased its holdings in Dyne Therapeutics by 11.8% during the fourth quarter.
E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after buying an additional 1,249 shares during the last quarter.
China Universal Asset Management Co. Ltd. raised its position in Dyne Therapeutics by 11.
7% during the fourth quarter. China Universal Asset Management Co. Ltd.
now owns 21,575 shares of the company’s stock worth $508,000 after acquiring an additional 2,265 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in Dyne Therapeutics by 21.4% in the fourth quarter.
Teacher Retirement System of Texas now owns 16,385 shares of the company’s stock valued at $386,000 after acquiring an additional 2,883 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.
Dyne Therapeutics Trading Up 6.1 %NASDAQ DYN opened at $7.47 on Tuesday.
The company has a market cap of $845.01 million, a price-to-earnings ratio of -2.10 and a beta of 1.
21. The company has a 50 day moving average of $11.70 and a 200-day moving average of $21.
06. Dyne Therapeutics, Inc. has a 1-year low of $6.
36 and a 1-year high of $47.45. Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th.
The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.
04. On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.
44 earnings per share for the current year. Analyst Ratings ChangesDYN has been the topic of several recent analyst reports. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th.
JPMorgan Chase & Co. lowered their price target on Dyne Therapeutics from $18.00 to $17.
00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th.
Chardan Capital reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, March 17th. Finally, Piper Sandler cut their price target on Dyne Therapeutics from $53.
00 to $48.00 and set an “overweight” rating for the company in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company.
According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.46.View Our Latest Research Report on DYNInsider ActivityIn other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction dated Tuesday, February 18th.
The stock was sold at an average price of $13.95, for a total value of $36,242.10.
Following the sale, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.
29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 6,237 shares of company stock valued at $77,760.
20.77% of the stock is currently owned by corporate insiders. Dyne Therapeutics Profile (Free Report)Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.Featured StoriesFive stocks we like better than Dyne TherapeuticsWhy Invest in 5G? How to Invest in 5G Stocks Why NVIDIA Stock Could Soar Despite Wall Street DowngradesWhat Are Dividend Challengers?Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldHow to Invest in Small Cap Stocks 3 Hot New IPOs Defying the 2025 Market Slump.
